Loading...
•
Dec 31, 2024
Ashland Q1 2025 Earnings Report
Ashland's financial performance in Q1 2025 was impacted by portfolio optimization and softer market conditions.
Key Takeaways
Ashland reported sales of $405 million, a 14% decrease compared to the prior-year quarter. The company experienced a net loss of $165 million, or $3.50 per diluted share. Adjusted EBITDA was $61 million, down 13% from the prior-year quarter. The company is maintaining its full-year fiscal 2025 outlook.
Sales decreased by 14% year-over-year to $405 million, with Portfolio Optimization reducing sales by approximately $50 million or 11%.
Loss from continuing operations was $166 million, or a loss of $3.51 per diluted share.
Adjusted income from continuing operations excluding intangibles amortization expense was $14 million, or $0.28 per diluted share.
Adjusted EBITDA decreased by 13% year-over-year to $61 million, with Portfolio Optimization reducing Adjusted EBITDA by approximately $8 million or 11%.
Ashland
Ashland
Ashland Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comPersonal Care Revenue
CapyFin.comSpecialty Additives Revenue
CapyFin.comIntermediates Revenue
CapyFin.com Forward Guidance
Ashland continues to expect full fiscal year sales in the range of $1.90 billion to $2.05 billion and Adjusted EBITDA in the range of $430 million to $470 million.
Positive Outlook
- Expanding high-performing business lines into new markets
- Commercializing new technology platforms
- Accelerating cost savings
- Optimizing its portfolio through the planned sale of Avoca
- Well-positioned to deliver on our goals with high-impact, self-help efforts underway
Challenges Ahead
- Weaker demand in Europe
- Effects of extended plant shutdowns
- Monitoring a potential European recovery
- Trade policy shifts
- Uncertainty surrounding potential trade policy changes
Revenue & Expenses
Visualization of income flow from segment revenue to net income